July 21, 2015
Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015
Conference Call and Webcast to Follow
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 21, 2015--
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second
quarter 2015 financial results will be released on Tuesday, July 28, at
4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead’s management
will host a conference call to discuss the company’s financial results
for the second quarter 2015 and provide a general business update.
The live webcast of the call can be accessed at the company’s Investors
page at www.gilead.com/investors.
Please connect to the company’s website at least 15 minutes prior to the
start of the call to ensure adequate time for any software download that
may be required to listen to the webcast. Alternatively, please call
1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial the
conference ID 73361664 to access the call. Telephone replay will be
available approximately two hours after the call through 11:59 p.m.
Eastern Time, July 30, 2015. To access the replay, please call
1-855-859-2056 (U.S.) or 1-404-537-3406 (international) and dial the
conference ID 73361664. The webcast will be archived on www.gilead.com
for one year.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases. Gilead has operations in more than 30
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150721006294r1&sid=acqr7&distro=nx&lang=en)
View source version on businesswire.com: http://www.businesswire.com/news/home/20150721006294/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Patrick O’Brien, 650-522-1936
Investor
Relations